Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis

Nav

General Info

Geography

South Africa (ZAF)

Coverage type

Country

Time period covered

01/2011 - 12/2016

Data type

Scientific literature

Keywords

Antibiotics, DALYs, HIV and AIDS, Health care costs, Health care economics, Tuberculosis

Citation

Authors

Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E

Journal

Appl Health Econ Health Policy

Volume

Issue

Pages

43-54

Publication year

2018

Suggested citation

Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Appl Health Econ Health Policy. 2018; 16(1): 43-54.

DOI

10.1007/s40258-017-0352-8

PMID

28980217

GHDx Entry last modified on: Apr 10, 2023

Header sites

Search form

Main menu

Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis

Nav